(S)-Carvedilol

小分子

(S)-卡维地洛

(2s)-1-(9h-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol | BDBM50167072 | (S)-BM 14190 | AS-82016 | AKOS030255655 | S-(-)-Carvedilol | E78791 | GW13D96IND | UNII-GW13D96IND | Q27279308 | Carvedilol, (-)- | DTXSID50241749 | (S)-(-)-Carv

(S)-Carvedilol

C648448-5mg

5mg

≥99%

-20°C储存

超低温冰袋运输

(S)-Carvedilol, the S-enantiomer of Carvedilol, is a non-selective β/α-1 blocker. (S)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX) In Vitro The β-receptor blocking activity of (S)-Carvedilol is about 100 times greater than that of (R)-Carvedilol, whereas both enantiomers show equipotent potency as α-blockers. (S)-Carvedilol significantly attenuates Doxorubicin (DOX)-induced cell death, apoptotic morphological changes, decrease the mitochondrial membrane potential and oxidative stress responses by increasing the superoxide dismutase and catalase activities, and decreasing malondialdehyde contents and reactive oxygen species levels via the PI3K/AKT/eNO synthase pathway in vitro. (S)-Carvedilol treatment significantly upregulates the expression levels of p-eNOS in HUVECs. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:β/α-1 adrenergic receptor

(S)-卡维地洛是卡维地洛的 S-对映体，是一种非选择性 β/α-1 阻滞剂。(S)-卡维地洛对多柔比星（DOX）的血管或心脏毒性具有保护作用。

95094-00-1

C24H26N2O4

406.47 g/mol

185395

COC1=CC=CC=C1OCCNC[C@@H](COC2=CC=CC3=C2C4=CC=CC=C4N3)O

(2S)-1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol

1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3/t17-/m0/s1

OGHNVEJMJSYVRP-KRWDZBQOSA-N

COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O

DMSO : 200 mg/mL (492.04 mM; Need ultrasonic)

3

5

10

406.189 Da

406.189 Da

75.700 Ų

30

0

508.000

0

1

4.200

1514452